SGHT — Stock Film
STOCK FILMSCENE 1/11SGHT · $8.21
Stock Expert AI presents
SGHT
Sight Sciences, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Sight Sciences, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 186 employees. Now — the numbers.

on the stock market since 2021
186 employees
$442.9M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.5.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
98%Surgical Glaucoma
Surgical Glaucoma 98%Dry Eye 2%
98% of all revenue comes from a single line: Surgical Glaucoma.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $40.8M
At this pace, that money lasts about 2.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
51
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
13
very weak

Clearly below the class average.

VALUATION
49
weak

Clearly below the class average.

GROWTH
41
weak

Clearly below the class average.

PRICE MOMENTUM
87
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $77.4M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $38.4M against $77.4M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, SGHT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: SGHT is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film